Express Mail No. ET347046184US
Filed: June 16, 2005

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/FLECTED OFFICE (DO/EO/US)

ATTORNEY'S DOCKET NUMBER PC27365

CON	CERNING A SUBMISSIC	U.S. APPLICATION NO. 4 known, see 37 CER 1.5)								
	TIONAL APPLICATION NO.	PRIORITY DATE CLAIMED								
	P2003/014801	December 20, 2002								
TITLE OF INVENTION ISOTOPE LABELED CAMPTOTHECIN DERIVATIVES										
APPLICANT(S) FOR DO/EO/US PHARMACIA ITALIA S.p.A.										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1. 🕱	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.									
2.	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.									
	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.									
4. 🔯	The US has been elected (Article 31).									
5. 100	A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
	a. X is attached hereto (required only if not communicated by the International Bureau).									
	b. X has been communicated by the International Bureau.									
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).									
	a. Lis attached hereto.									
T.	b. LJ has been previously submitted under 35 U.S.C. 154(d)(4).									
7. LXI	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))									
	a. I are attached hereto (required only if not communicated by the International Bureau).									
	b. have been communicated by the International Bureau.									
	c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made.									
, \Box	c. — Have not been made and t	ne amendments to the claims under PCT Art	icle 19 (35 I I S C 371(c)(3))							
<u>.</u> □	An oath or declaration of the inventor	•	ide 19 (33 0.3.0. 37 1(c)(3)).							
10. 🔀		e annexes of the International Preliminary E	xamination Report under PCT							
Items 11 to 20 below concern document(s) or information included:										
11.	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.								
12.	An assignment document for recording	ng. A separate cover sheet in compliance wi	th 37 CFR 3.28 and 3.31 is included.							
13	A preliminary amendment.									
14. 🛚 🗵	An Application Data Sheet under 37 0	OFR 1.76.								
15.	A substitute specification.									
16.	A power of attorney and/or change of	address letter.								
17.	A computer-readable form of the sequ	uence listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821- 1.825.							
18.	A second copy of the published Interr	national Application under 35 U.S.C. 154(d)((4).							
19.	A second copy of the English language	ge translation of the international application	under 35 U.S.C. 154(d)(4).							
20	Other items or information:									

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

JC17 Rec'd PCT/PTO 16 JUN 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (it knows see 376FT 1.5) INTERNATIONAL APPLICATION NO. PCT/EP2004/014801				ATTORNEY'S DOCKET NUMBER					
L	0794	PC27365							
i .	wing fees have t	CALCULATIONS	PTO USE ONLY						
21. 🔯 Basio	national fee	•••••		\$300	\$300.00				
If International pr	(1)-(4)	\$ 200.00							
Search fee (37 CI	nal Searching Aut och Report prepar	\$400.00							
	TOTAL OF 21, 2	2 and 23 =			\$900.00				
Additional fee	for specification ting or computer 50 for each addi								
Total Sheets			h additional 50 or fraction up to a whole number)	RATE					
- 100 =	/50 =			× \$250	\$				
Surcharge of \$13 claimed priority da		\$							
CLAIMS	NUME	ER FILED	NUMBER EXTRA	RATE	\$				
Total claims		- 20 =		x \$50	\$				
Independent clain	ns	- 3 =		x \$200	\$				
MULTIPLE DEPE	NDENT CLAIM(S	S) (if applicable)		+ \$360	\$				
			TOTAL OF ABOVE	CALCULATIONS =	\$				
Applicant clai	ms small entity s								
		\$							
Processing fee of claimed priority da		\$							
			TOTAL	NATIONAL FEE =	\$				
Fee for recording by an appropriate		\$							
			TOTAL F	EES ENCLOSED =	\$				
		Amount to be refunded:	\$						
		Amount to be charged:	\$ 900.00						
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge my Deposit Account No. 16-1445 in the amount of \$ 900.00 to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-1445. A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CORF	I F. Ch	\mathcal{L}							
Pfizer Inc Patent Dep									
150 East		Kershner							
New York,									
		ON NUMBER							